Rhodiola rosea for Health & Longevity

Created on 11/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Rhodiola rosea is an herbal root extract used to help cope with stress. Evidence suggests, but has not independently confirmed, modest short-term relief of stress-related mental fatigue, and supports a small endurance boost when taken shortly before exercise. Longevity evidence is laboratory-only, untested in mammals or people. Trial side effects were mild; main risks are mislabeled products, modestly slower liver breakdown of some medicines such as warfarin, and possible over-activation. (Full Review)

Protocol

Fatigue and stress (SHR-5)
170–576 mg/day
Night duty to burnout; the extract maker sponsored these regimens
Endurance exercise
200 mg or 3 mg/kg
One hour before exercise
Time of day
Morning
Second dose by early afternoon; evening doses risk insomnia
Time to effect
Endurance exercise
Within one hour
Acute exercise effects
Fatigue and mood
2–12 weeks
Duration of fatigue and mood trials
Stress
3 days
Open-label stress improvements reported

Benefits

Contraindications
  • Children and adolescents under 18
  • Pregnancy and breastfeeding
  • Bipolar disorder or history of mania
  • People on warfarin or phenytoin without monitoring
  • Known allergy to Rhodiola or its products
Key Interactions
  • CYP2C9 substrates (warfarin, phenytoin, losartan)
  • Serotonergic antidepressants (paroxetine)
  • Sertraline (tested together)
Theoretical (inferred from mechanism)
  • Monoamine oxidase inhibitors (selegiline, phenelzine)
  • Serotonergic supplements (St John's wort, 5-HTP)
  • Other adaptogens (ashwagandha, Schisandra)
  • Prescription stimulants (modafinil, methylphenidate)
  • Sedative-hypnotics (zolpidem)
  • P-glycoprotein substrates (digoxin)
  • Glucose-lowering drugs (metformin, insulin)
  • Blood-pressure-lowering drugs (amlodipine, lisinopril)
  • Immunosuppressants (such as tacrolimus) and anti-inflammatory drugs (ibuprofen)

Risk & Side Effects

  • High:
  • Medium: Mild adverse events
  • Low: Reduced CYP2C9 drug clearance; serotonergic or heart-rhythm reaction with antidepressants; mania, overstimulation or insomnia; perioperative bleeding
  • Speculative: Product adulteration and contamination; loss of benefit at high doses

Monitoring

Marker Target Why
INR (warfarin users only) 0.8–1.2 (standard reference range); track change from pre-Rhodiola INR Safety check on warfarin effect
Perceived Stress Questionnaire or Perceived Stress Scale score No established target; track change from own baseline Primary stress outcome
Multidimensional Fatigue Inventory (MFI-20) score No established target; track change from own baseline Fatigue outcome
Salivary cortisol awakening response No established target; track change from own baseline Shifted with treatment in burnout
Endurance time trial or time to exhaustion No established target; track change from own baseline Endurance outcome

Cadence: Baseline before starting; questionnaires and diary at 2 weeks, 4 weeks and at the end of each course (usually 8–12 weeks); INR 1–2 weeks after starting, changing or stopping the extract; performance test every 4–6 weeks.

Qualitative Assessment

  • Afternoon energy and resistance to mental fatigue during demanding work
  • Concentration and error rate on routine tasks
  • Mood, irritability and anxiety under stress
  • Sleep onset and sleep quality (watch for worsening)
  • Perceived effort during familiar workouts